FDA 483 - Baxter Pharmaceuticals India Pvt Ltd - January 27, 2023

The FDA inspected Baxter Pharmaceuticals India Pvt Ltd from January 19 to January 27, 2023, issuing a Form 483 that cited numerous deviations from Current Good Manufacturing Practices (cGMP). Significant observations included a widespread failure to thoroughly investigate unexplained discrepancies and batch failures. This encompassed inadequacies in automatic visual inspection processes, where deficient equipment continued in use, and scientifically unsound root cause investigations for Out-of-Specification (OOS) results in product purity and particulate matter. The facility also exhibited poor equipment maintenance, with damaged and unclean components often tagged as 'cleaned.' Cleaning procedures themselves lacked detail and verification, leading to potential contamination risks. Operational and facility design issues were noted, hindering aseptic operations and proper cleaning. Furthermore, the inspection uncovered deficiencies in production and process controls, with visual inspectors failing to adhere to procedures and lacking scientific rationale for acceptance criteria. Critical gaps in preventing microbiological contamination, such as unestablished product hold times and gowning breaches, were observed. Data integrity was compromised by the destruction of original GMP documents and uncontrolled record-keeping practices. Finally, laboratory controls were found inadequate, with an unregistered R&D unit performing analytical method validation without proper oversight or scientifically sound procedures. Baxter Pharmaceuticals India Pvt Ltd must implement comprehensive corrective and preventive actions to address these findings and ensure compliance with regulatory standards.